Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard
M J
MJ
Department of Molecular and Cellular Pathology, Ninewells Medical School, Dundee, UK.
Weatherall
D J
DJ
D015913:Chelation Therapy / Q000009:adverse effects*; D000077543:Deferiprone; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000209:etiology / Q000517:prevention & control*; D008103:Liver Cirrhosis / Q000139:chemically induced; D011728:Pyridones / Q000009:adverse effects* / Q000627:therapeutic use; D065227:Transfusion Reaction; D017086:beta-Thalassemia / Q000628:therapy*
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine